FDA Can't OK More Crestor Generics, AstraZeneca Says
The U.S. Food and Drug Administration can't approve additional generic versions of cholesterol drug Crestor because of remaining exclusivity for one indication, AstraZeneca Pharmaceuticals LP said in a citizen petition released...To view the full article, register now.
Already a subscriber? Click here to view full article